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Abstract
Background: Cancer cells have a different metabolic profile compared to normal cells. The Warburg effect
(increased aerobic glycolysis) and glutaminolysis (increased mitochondrial activity from glutamine catabolism) are
well known hallmarks of cancer and are accompanied by increased lactate production, hyperpolarized
mitochondrial membrane and increased production of reactive oxygen species.
Methods: In this study we target the Warburg effect with dichloroacetate (DCA) and the increased mitochondrial
activity of glutaminolysis with arsenic trioxide (ATO) in breast cancer cells, measuring cell proliferation, cell death
and mitochondrial characteristics.
Results: The combination of DCA and ATO was more effective at inhibiting cell proliferation and inducing cell
death than either drug alone. We examined the effect of these treatments on mitochondrial membrane potential,
reactive oxygen species production and ATP levels and have identified new molecular mechanisms within the
mitochondria for both ATO and DCA: ATO reduces mitochondrial function through the inhibition of cytochrome C
oxidase (complex IV of the electron transport chain) while DCA up-regulates ATP synthase b subunit expression.
The potentiation of ATO cytotoxicity by DCA is correlated with strong suppression of the expression of c-Myc and
HIF-1a, and decreased expression of the survival protein Bcl-2.
Conclusion: This study is the first to demonstrate that targeting two key metabolic hallmarks of cancer is an
effective anti-cancer strategy with therapeutic potential.
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Introduction
Arsenic trioxide (ATO) has been used as a therapeutic
agent for over 2000 years. Originating from China [1], it
is currently being used against acute promyeloid leuke-
mia (APL) in patients who have relapsed following all-
trans-retinoic acid/anthracycline therapy and is being
promoted for first line therapy of de novo APL [2-4].
ATO is known as a hyper-reactive molecule and could
potentially bind to thiol groups in many proteins [2,5].
Its ability to bind to the thiol-rich, mutant protein
PML-RAR-a produced from a chromosome transloca-
tion in APL has made it an effective drug in APL
[2,5,6]. ATO has been shown to induce apoptosis in a
variety of cancer cell lines in vitro and in vivo [7,8], but
it has been difficult to consider ATO for clinical use in
tumor types other than APL due to the lack of knowl-
edge of the molecular targets that result in its cytotoxi-
city. In the past 10 years, physiological changes within
cancer cells in response to ATO treatment have been
well characterized, and many clinical trials for new
applications of ATO are underway [5]. ATO has been
proposed as a mitochondrial toxin [9]. ATO can depo-
larise the mitochondrial membrane potential (MMP)
[10], increase intracellular reactive oxygen species (ROS)
production [8], and induce apoptosis [8]. The proposed
target for ATO that can achieve these phenotypic
changes is the mitochondrial transition pore (MTP)
[11]. ATO has been shown to induce the opening of the
MTP, which induces cytochrome c release and is pro-
posed to dissipate the MMP and increase ROS release
from the mitochondria [12]. More recently, the thiore-
doxin system, in particular thioredoxin reductase, has
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also been identified as a target of ATO that may contri-
bute to increased oxidative stress and altered redox sig-
nalling after ATO treatment of cancer cells [9,13].
The Warburg effect is a wide spread phenomenon that
has been identified in over 90% of all tumor forms. Cells
that exhibit the Warburg effect take on alternative routes
of energy homeostasis to maintain their proliferative phe-
notype [14]. Nobel laureate Dr Otto Warburg stated that
cancer cells rely on glycolysis or substrate phosphorylation
to generate ATP, and suppress their mitochondrial activ-
ities [15]. With more advanced technologies, recent stu-
dies have confirmed the ATP production aspect of the
Warburg hypothesis but revealed that mitochondrial activ-
ity is not suppressed in cancer cells. Instead mitochondria
play vital roles in providing substrates to maintain cell
division [16].
The anti-cancer effect of reversing the Warburg effect
has been described recently and an old drug dichloroace-
tate (DCA), which can redirect ATP synthesis from glyco-
lysis to oxidative phosphorylation, has demonstrated good
anti-cancer activity both in vitro [17-19] and in vivo
[20-23]. DCA is a pyruvate dehydrogenase kinase inhibi-
tor, and results in increased pyruvate dehydrogenase activ-
ity [19]. This leads to the increased conversion of pyruvate
to acetyl-CoA rather than lactic acid as described by the
Warburg effect, and stimulates mitochondrial respiration
by increasing the supply of acetyl-CoA. Consequently,
after DCA treatment, cancer cells showed increased levels
of ROS, depolarization of the MMP in vitro and increased
apoptosis both in vitro and in vivo [17,20].
As DCA can redirect substrates into mitochondrial
respiration and ATP production, it could have a syner-
gistic activity with anti-cancer drugs that impair mito-
chondrial activity. We propose that by reversing the
glycolytic phenotype with DCA and directing more pyr-
uvate into mitochondrial oxidative phosphorylation,
while simultaneously targeting the mitochondria with
ATO, a severe disruption of energy homeostasis will
occur within cancer cells. In this study we show that in
combination DCA and ATO work together to inhibit
the growth of breast cancer cell lines in vitro. Further,
we have identified new molecular mechanisms within
the mitochondria that can contribute to the cytotoxicity
of ATO providing additional support for the use of
ATO against solid tumours.
Materials and methods
Reagents
JC-1, CFSE and H2DCFDA were from Invitrogen (Carls-
bad, CA, USA), CellTiter-Glo and Caspase-Glo assay
kits were purchased from Promega Co (San Luis, CA,
USA). The rest of the chemicals were purchased from
Sigma Co (St. Louis, MO, USA).
Cell culture
Cell lines were obtained from the following sources in
the years indicated. Dr Anna DeFazio, Westmead Millen-
ium Institute, Sydney, Australia: T-47D (2003), BT-20
(2003), MCF-10A (2005) and MCF-10AT1 (2005); Prof
Chris Parish, Australian National University, Canberra,
Australia: 13762 MAT (2007), MDA-MB-468 (2003) and
MDA-MB-231 (2003). The cell lines have appearances
consistent with published morphologies, but have not
been authenticated recently. Human breast epithelial car-
cinoma cells (T-47D) were grown in RPMI 1640 medium
supplemented with 10% fetal bovine serum in the pre-
sence of 0.1% PSN (3% penicillin, 5% streptomycin and
5% neomycin). BT-20, MDA-MB-231, MDA-MB-468,
and 13762 MAT cell lines were maintained in DMEM/F-
12 medium supplemented with 10% FBS and 2 mM
L-glutamine. DMEM/F-12 medium with 25% horse
serum, 0.01% EGF, 0.28 IU/ml insulin, 0.01% cholera
toxin and 0.5 μg/ml hydrocortisone used for MCF-10A
and MCF-10AT1 cells. All of the cell lines were main-
tained at 37°C in 5% CO2.
Cell viability
For the assessment of cell viability, cells were plated in 96
well plates at a density of 3000 cells per well and 8 wells
per group. Following exposure to DCA and ATO for 24
to 72 hours, cells were incubated for 3 hours with neutral
red (30 μg/ml) in fresh media, then washed with PBS, fol-
lowed by the addition of lysis buffer (acetic acid/metha-
nol, 80%/20%) and the absorbance at 540 nm was
recorded. Results are expressed as mean ± S.D, calcula-
tions were performed using the Prism software package,
ANOVA with Tukey post test was applied and P < 0.05
was considered to be statistically significant. Experiments
were performed at least three times and data presented
are of one representative experiment.
Cell proliferation
T-47D cells were harvested and resuspended in 1 ml of
RPMI medium. Cells were labelled by the addition of 1
ml of PBS containing 5 μM The carboxyfluorescein suc-
cinimidyl ester (CFSE), followed by 5 min incubation at
room temperature. Labelled cells were then washed
twice, counted and seeded at 105 cells/well in a 12 well
plate. On the day of analysis, T-47D cells were harvested
and washed twice with PBS and then CFSE intensity was
examined by FACS. Results are expressed as mean ± S.D
(n = 3), calculations were performed using the Prism
software package, ANOVA with Tukey post test was
applied and P < 0.05 was considered to be statistically
significant. Experiments were performed at least three
times and data presented are of one representative
experiment.
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Cell death
Apoptosis was quantitated by flow cytometry after staining
cells with FITC-labelled Annexin-V (AV) (Invitrogen Co.)
and propidium iodide (PI). After drug treatment, T-47D
cells were harvested and centrifuged at 1200 rpm for
5 min; the pellets were washed twice with PBS and then
resuspend in 100 μl of Annexin-V binding buffer (0.14 M
NaCl, 2.5 mM CaCl2, 0.01 M HEPES pH 7.4). Annexin-V
(1 μL) and 5 μl of PI (50 μg/ml) were added to the samples
and incubated in the dark for 15 min. Samples were kept
on ice after incubation until FACS analysis was performed.
Results are expressed as mean ± S.D (n = 3), calculations
were performed using the Prism software package,
ANOVA with Tukey post test was applied and P < 0.05
was considered to be statistically significant. Experiments
were performed at least three times and data presented
are of one representative experiment.
ROS generation
For the assessment of intracellular ROS levels, cells were
plated in 12 well plates with cell density of 1 × 105 cells
per well and treated with drugs for 12 hours. 2’, 7’-dihy-
drochlorofluroresceinacetate (H2DCFDA) was added to
the medium at a final concentration of 10 μM and the
cells were allowed to stain for 1 hour in the dark. After
H2DCFDA staining, cells were trypsinized, washed twice
and resuspended in 100 μl of PBS. H2DCFDA intensity
was examined using FACS. Results are expressed as
mean ± S.D (n = 3), calculations were performed using
the Prism software package, ANOVA with Tukey post
test was applied and P < 0.05 was considered to be statis-
tically significant. Experiments were performed at least
three times and data presented are of one representative
experiment.
ATP concentration and Caspase activity
Internal ATP level and caspase activity in T-47D cells
was assessed using CellTiter-Glo and Caspase-Glo 3/7
assay kits (Promega Corp., Madison, WI) according to
the manufacturer’s instructions. T-47D cells were cul-
tured in the absence and presence of drugs for 12 hours
in white opaque 96 well plates (4 wells per group). Equal
volumes of CellTiter-Glo reagents were added after
which the samples were incubated for 15 min on a shaker
at room temperature. Luminescence was recorded using
the Glomax micro-plate luminometer (Promega Co.,
Madison, WI) under the preset CellTiter protocol.
Results are expressed as mean ± S.D (n = 4), calculations
were performed using the Prism software package,
ANOVA with Tukey post test was applied and P < 0.05
was considered to be statistically significant. Experiments
were performed at least three times and data presented
are of one representative experiment.
Mitochondrial membrane potential
Similarly to the measurement of ROS, cells were plated in
12 well plates with cell density of 1 × 105 cells per well
and treated with drugs for 12 hours. 5, 5’, 6, 6’-tetra-
chloro-1, 1’, 3, 3’-tetraethylbenzimidazol-carbocyanine
iodide (JC-1) was added in the medium at a final concen-
tration of 0.2 μM and the cells were allowed to stain for
30 min in the dark. After JC-1 staining, cells were trypsi-
nized, washed twice with PBS and resuspended in 100 μl
of PBS. JC-1 intensity was examined using FACS. Results
are expressed as mean ± S.D (n = 3), calculations were
performed using the Prism software package, ANOVA
with Tukey post test was applied and P < 0.05 was con-
sidered to be statistically significant. Experiments were
performed at least three times and data presented are of
one representative experiment.
Cytochrome C oxidase activity
Cytochrome C oxidase assay was assessed based on the
method previously published [24]. Briefly, after drug
treatment in 96 well plates (8 wells per group), T-47D
cells were permeabilized with 50 μl of 0.01% saponin, fol-
lowed by the addition of 100 μl substrate medium (4 mM
3,3-diaminobenzidine tetrahydrochloride (DAB), 100 μM
reduced cytochrome C, 2 μg/ml catalase in 0.1 M Na
phosphate, pH 7.0). Absorbance at 450 nm was measured
immediately after the addition of substrate medium and
monitored over 30 min. Results are expressed as mean ±
S.D (n = 8), calculations were performed using the Prism
software package, ANOVA with Tukey post test was
applied and P < 0.05 was considered to be statistically
significant. Experiments were performed at least three
times and data presented are of one representative
experiment.
PDH activity
PDH activity was measured using the MitoSciences PDH
enzyme activity microplate assay kit (#MSP18, MitoS-
ciences, Oregon USA). For measuring the effect of drugs
on PDH activity in cells, T-47D cells were treated with
drugs in media for 3 hrs, after which they were washed
and resuspended in PBS. Cell extracts were prepared and
assayed for PDH activity at a concentration of 15 mg pro-
tein/ml, according to the kit instructions. For measure-
ment of direct inhibition of PDH by ATO, PDH was
isolated from untreated T-47D cells by applying cell
extracts to the antibody capture plate. After washing the
plate, assay solution containing drug was added to the
wells and then immediately assayed for activity PDH.
Results are expressed as mean ± S.D (n = 4), calculations
were performed using the Prism software package,
ANOVA with Tukey post test was applied and P < 0.05
was considered to be statistically significant. Experiments
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were performed at least three times and data presented
are of one representative experiment.
Immunoblotting and densitometric analysis
Cells (1 × 106) were plated in T25 tissue culture flasks
and were treated with ATO or DCA for 12 hours. Cell
lysates were prepared by the addition of 500 μl of the M-
PER® mammalian protein extraction reagent (Thermo
Scientific, IL, USA). Immunoblotting was performed as
described previously [25], using the antibodies for c-Myc
(Roche, IN, USA, clone 9E10), HIF-1a (Abcam, Cam-
bridge, UK, #ab82832), Bcl-2 (Abcam #ab692), ATP
synthase b-subunit (Abcam #ab14730) and b-actin
(Abcam #ab8227). Western blots were detected using
chemiluminescence and exposure of x-ray film. Images
were acquired using a CanoScan 8600F flatbed scanner,
and quantitated using the ImageJ software (version 1.4,
NIH, USA) and standardized to b-actin in each lane.
Results were pooled from 3 separate experiments and
expressed as mean ± S.D (n = 3), calculations were per-
formed using the Prism software package, ANOVA with
Tukey post test was applied and P < 0.05 was considered
to be statistically significant.
Results
DCA and ATO together are more effective at reducing cell
proliferation and inducing cell death
To investigate the combined effect of ATO and DCA at
inhibiting cell growth, breast cancer cell lines were trea-
ted for several days with both drugs and total cell num-
ber was assessed using the neutral red cell viability assay.
The panel of cell lines represent the major subtypes of
human breast cancer (luminal (T-47D), basal A (MDA-
MB-468, BT-20), basal B (MDA-MB-231)), or have other
relevance as experimental models (13762MAT - rat
mammary adenocarcinoma sensitive to DCA in vivo [22],
MCF10AT1 - malignant derivative of immortalized cells
MCF-10A). MDA-MB-468, MDA-MB-231, and T-47D
cells all showed a significant reduction ranging from 10%
to 40% in total cell number after 72 hours treatment with
5 mM DCA (Figure 1A) while 13762 MAT, BT-20 and
MCF-10AT1 cells did not respond during the treatment
period. All of the cancer cell lines tested were sensitive to
ATO but at different concentrations. A reduction in total
cell number was seen in BT-20, T-47D, MCF-10AT1 and
MDA-MB-468 with only 5 μM ATO treatment, however
15 μM ATO was required to achieve the same efficiency
in MDA-MB-231 and 13726 MAT cell lines. Strikingly,
DCA and ATO in combination showed a greater effect
than either drug alone in all of the cancer cell lines
tested. Where ATO and DCA were effective as single
agents at reducing cell numbers, the effect of combined
treatment was approximately equal to the sum of the
individual drug effects (T-47D, MDA-MB-468 and
MDA-MB-231). Where DCA alone showed no reduction
in cell number, it was still able to enhance the growth
inhibition of ATO by 2-3 fold (13762 MAT, BT-20 and
MCF10AT1) (Figure 1A). The non-cancerous cell line,
MCF-10A showed no reduction in cell number after
ATO (15 μM), DCA (5 mM) or combined treatment.
The effect of ATO and DCA was examined further with
T-47D cells, one of the cell lines more sensitive to DCA
alone. The response of T-47D cells towards DCA was
dose-dependent and after 72 hours, 5 mM DCA treated
cells had 42 ± 6% less cells than the control culture (Figure
1B). ATO alone (5 μM) reduced the total cell number by
56 ± 4% and cells treated with both DCA and ATO
showed a further decrease compared to the ATO only
group (Figure 1C). The dose response curve showed that
combination treatment of DCA (5 mM) and ATO can
reduce the IC50 to 0.25-fold that of ATO alone (Figure
1C). This effect is occurring within the concentration
range achieved clinically for ATO (up to 5-7 μM [26]).
CFSE proliferation assay demonstrated that either
ATO (5 μM) or DCA (5 mM) treated cells emitted sig-
nificantly higher CFSE fluorescence (2.1-fold and 2.2-
fold respectively) after 72 hours of treatment indicating
growth inhibition. Cells treated with both ATO and
DCA showed a 3.4-fold increase in CFSE intensity com-
pared to untreated cells indicating the drugs worked
together at inhibiting cell proliferation (Figure 1D).
The effect of ATO and DCA on T-47D cell death was
assessed using AV and PI double staining and cells were
analysed using fluorescent cell sorting. DCA alone (5 mM)
did not induce cell death in T-47D cells (Figure 1E), simi-
lar to the effect of DCA on 13762 MAT cells reported pre-
viously [22]. ATO (5 μM) also failed to induce cell death
after 12 hours of treatment, however cells treated with
both 5 μM ATO and 5 mM DCA showed a small (15%)
increase in AV+/PI+ population (13.2 ± 0.6% apoptotic
cells compared to 11.5 ± 1.0% for ATO/DCA vs. untreated
respectively, p = 0.07), suggesting that DCA may be
enhancing the apoptotic effects of ATO. At higher con-
centrations and with 48 hours of treatment, ATO (20 μM)
increased the amount of cell death by 35 ± 8% (P = 0.029)
compared to the untreated culture (Figure 1E). Combining
5 mM DCA with 20 μM ATO treatment resulted in a
4-fold greater increase in the AV+/PI+ population com-
pared to ATO alone, indicating that DCA can potentiate
the cell death induced by ATO in T-47D breast cancer
cells (Figure 1E).
ATO and DCA work together on depolarising the MMP
but have counter effects on inducing ATP and ROS
production
Both ATO and DCA have been shown to alter mito-
chondrial function, depolarizing MMP and increasing
ROS production [20]. Therefore these parameters along
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Figure 1 Inhibition of cancer cell growth by ATO and DCA. (A) Combined effect of ATO (5 or 15 μM) and DCA (5 mM) on breast cancer cell
growth as measured by neutral red viability assay after 3 days of treatment. BT-20, T-47D, MDA-MB-468 and MCF-10AT1 cells were treated with 5
μM ATO. MDA-MB-231, MAT and MCF-10A cells were treated with 15 μM ATO. (B) Dose response of T-47D cells towards DCA (t = 72 hours). (C)
Dose response of T-47D cells towards ATO and ATO/DCA (5 mM) treatment (t = 72 hours). (D) T-47D proliferation measured as mean CFSE
intensity after treatment with 5 μM ATO and/or 5 mM DCA (t = 72 hours) (higher CFSE intensity indicating less proliferation). (E) Cell death (AV
+/PI+) population expressed as percentage of total cell number after 48 hours of treatment with 20 μM ATO and/or 5 mM DCA. * P ≤ 0.05, ** P
≤ 0.001, *** P ≤ 0.0001, NS - not significant (treated vs untreated). ## P ≤ 0.001, ### P ≤ 0.0001 (ATO/DCA vs ATO).
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with ATP level were studied in an effort to determine
whether they contribute to the enhanced anti-cancer
effects of ATO/DCA combined treatment. Measured by
JC-1 staining, the number of T-47D cells with a hyperpo-
larized MMP (upper right quadrant) was significantly
decreased by DCA (5 mM) or ATO (5 μM and 20 μM)
treatment (t = 12 hours) (28 ± 6%, 38 ± 4% and 69 ± 7%
decrease respectively compared to untreated control
cells), consistent with previously published data [20,27].
Combining ATO (5 μM or 20 μM) with 5 mM DCA lead
to an even greater decrease (53 ± 9% and 77 ± 12%
respectively) compared to the untreated cells (Figure 2A),
demonstrating that DCA and ATO can work together in
depolarizing the MMP. ATP levels were decreased by
both low and high dose ATO (14 ± 3% and 32 ± 5%
respectively) after 12 hours of treatment, while DCA
Figure 2 Intracellular responses of T-47D cells to ATO and DCA treatment. (A) JC-1 staining showing the combined effect of DCA and ATO
at depolarizing the MMP (t = 12 hours). (B and C) The effects of ATO (20 μM (B) or 5 μM (C)) and DCA (5 mM) on ATP levels. * P ≤ 0.05, ** P ≤
0.001, NS - not significant (treated vs untreated).
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treated cells showed a 6 ± 1% increase in ATP levels (Fig-
ure 2B and 2C). At the high dose of ATO, DCA was
unable to increase ATP production (Figure 2B), whereas
at the low dose of ATO, DCA and ATO combined trea-
ted cells showed a small increased in ATP production
over ATO treatment alone (Figure 2C). This data indi-
cates that DCA and ATO are affecting ATP production
via separate targets inside the cells.
Increased intracellular ROS levels have been proposed to
be the reason behind ATO cytotoxicity [2,9]. The com-
bined effect of ATO and DCA on ROS was investigated
using the fluorescent stain H2DCFDA. Cells treated with
20 μM ATO or 5 mM DCA showed elevated intracellular
ROS levels (2.8 and 1.9-fold respectively) (Figure 3A) simi-
lar to previously published results [27], while cells treated
with both ATO and DCA showed a further increase (5.2-
fold) in ROS production.(Figure 3A). In contrast, low con-
centration ATO (5 μM) induced a 0.5-fold decrease in
ROS production (Figure 3B). This was contrary to pre-
vious reports on ROS production and ATO treatment, so
the dose-response and time course of ROS production
after ATO treatment was analysed. This revealed that
lower concentrations of ATO decreased intracellular ROS
production while high ATO induced ROS production
(Figure 3C). Similarly 10 μM ATO treatment resulted in a
notable decrease in ROS production in the first 4 hours
before ROS levels increased after 8 hours to the level
reported by others (Figure 3D). Combined treatment of
cells with 5 mM DCA and 5 μM ATO resulted in an inter-
mediate ROS production (Figure 3B) similar to untreated
cells.
The intermediate effects of DCA/ATO combination
treatment on ATP and ROS levels may be explained by
competing effects on PDH activity. DCA targets PDK, and
therefore should increase PDH activity, whereas ATO has
been reported to inhibit PDH either directly by reaction
with vicinal thiols on PDH or indirectly via increased
hydrogen peroxide production [28]. To examine the
effects of ATO and/or DCA on PDH activity, intact cells
or PDH isolated from T-47D cells, were treated with drug
Figure 3 Effects of ATO and DCA on ROS production. (A and B) The effects of ATO and DCA on ROS levels in T-47D cells after either 20 μM
(A) or 5 μM (B) ATO treatment, alone and in combination with 5 mM DCA. (C) Dose response of ROS levels towards different concentrations of
ATO (t = 12 hours). (D) Time course of ROS production after 10 μM ATO treatment. ** P ≤ 0.001, *** P ≤ 0.0001, NS - not significant (treated vs
untreated).
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and the PDH activity determined. As predicted, 3 hr treat-
ment of intact cells with DCA resulted in increased PDH
activity, whereas ATO (up to 20 μM) did not alter PDH
activity of intact cells (Figure 4A). In contrast, DCA did
not change the activity of isolated PDH, but high concen-
trations of ATO were able to inhibit PDH activity (Figure
4b). Thus in T-47D cells, ATO did not decrease PDH
activity at the concentrations used in this study.
ATO is an inhibitor of complex IV of the electron
transport chain
The electron transport chain (ETC) is located in the
inner membrane of the mitochondria and plays a vital
role in energy production. The ETC is responsible for
generating the proton gradient for the inner membrane
space of mitochondria to maintain the MMP for ATP
production [29]. The ETC is also documented as the
major site of ROS production within cells as a result of
electron leakage from complex I and III [30]. Due to its
ability to lower ROS, depolarize MMP and decrease
ATP production simultaneously, we have hypothesised
that ATO operates as an ETC inhibitor. A panel of ETC
inhibitors was compared to ATO (5 μM) to identify
whether they induce the same phenotypic changes as
ATO in T-47D cells. Rotenone (0.1 μM, complex I), the-
nolytrifluoroacetone (TTFA) (10 μM, complex II), anti-
mycin (0.1 μM, complex III) and NaCN (10 mM,
complex IV) were used to treat T-47D cells and ROS,
MMP and ATP levels were compared to ATO treated
cells. All of the inhibitors demonstrated abilities to
depolarize MMP (Figure 5A) and reduce ATP levels
(Figure 5B) similarly to ATO. However, in contrast to
ATO, rotenone, antimycin and TTFA failed to reduce
ROS production within cells, instead elevating ROS 3-
to 6-fold after 12 hours treatment (Figure 5C). Cells
treated with NaCN (10 mM) however, showed a 52%
decrease in ROS production (Figure 5C) similar to ATO
treatment. Based on these data we concluded that in T-
47D breast cancer cells, the inhibition of complex IV of
the ETC but not complexes I-III results in a reduction
of ROS, and therefore it is likely that phenotypic
changes induced by ATO are caused by the inhibition
of complex IV (cytochrome C oxidase) of the ETC. To
confirm this, cytochrome C oxidase activity in T-47D
cells was measured spectrophotometrically. Cytochrome
C oxidase assay clearly demonstrated that while DCA
had no effect on complex IV activity, ATO (5 μM, 5
min) can inhibit complex IV activity confirming our
hypothesis (Figure 5D). Similar results were obtained
after 10 min, 3 hr and 12 hr drug treatments. The com-
bination of ATO and DCA showed similar enzyme inhi-
bition to ATO alone.
Mitochondrial transition pore inhibitors partially blocked
ATO induced caspase activation but had no effect on
ROS, ATP and MMP
One mechanism that has previously been described as
the key to ATO cytotoxicity is the opening of the mito-
chondrial transition pore (MTP). ATO has been shown
to induce the opening of the MTP in isolated mitochon-
dria and can increase cytochrome C release [11] and
induce nuclear apoptosis in cell free systems [31]. The
Figure 4 Effects of ATO and DCA on PDH activity. (A) The effects of on PDH activity in T-47D cells after 3 hr of treatment with ATO and
DCA. (B) Effect of ATO treatment on the PDH activity of isolated PDH (antibody capture from T-47D cells). * P ≤ 0.05, ** P ≤ 0.001, *** P ≤
0.0001, NS - not significant (treated vs untreated).
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opening of MTP by ATO has been proposed to induce
mitochondrial permeabilization, dissipate the MMP and
increase intracellular ROS. To test whether the MTP is
important for ATO toxicity in T-47D cells, bongkrekic
acid (BA) and cyclosporine A (CsA), both potent MTP
pore blockers [32], were combined with ATO to see
whether they can inhibit ATO induced intracellular
changes. The addition of 5 μM CsA or 50 μM BA to
ATO (5 μM) treated cells did not interfere with the abil-
ity of ATO to lower ROS production after 12 hours of
treatment, decrease ATP production or depolarise the
MMP (P > 0.05) (Figure 6B, C and 6D). Similar data can
be seen for NaCN and CsA/BA treatment (P > 0.05)
(Figure 6B, C and 6D). To confirm the activity of CsA
and BA in our experimental conditions, caspase 3/7
activity, an apoptosis marker downstream of MTP open-
ing, activated by cytochrome C release, was assessed
after high concentration ATO treatment (Figure 6A).
ATO treatment (20 μM) doubled caspase 3/7 activity
compared to untreated cells (2.1-fold, Figure 6A) and
this effect was decreased by BA and CsA (1.7-fold and
1.4-fold, respectively), indicating that CsA or BA can
block MTP opening in T-47D cells. These data clearly
demonstrate that although ATO (20 μM) can induce
the opening of MTP, this mechanism cannot explain the
ROS, MMP and ATP changes occurring during 5 μM
ATO treatment. We conclude that these alterations are
likely due to the inhibition of ETC complex IV.
Figure 5 Inhibition of the ETC by ATO. (A to C) The effects of a series of ETC inhibitor treatments were compared to 5 μM ATO (t = 12
hours): (A) MMP by JC-1 staining; (B) ATP levels; (C) ROS levels. (D) Cytochrome C oxidase activity after treatment (5 min) with DCA (5 mM)
and/or ATO (5 μM). ** P ≤ 0.001, *** P ≤ 0.0001, NS - not significant (treated vs untreated).
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DCA and ATO have opposing effects on ATP synthase b-
subunit and Bcl-2 expression while working co-
operatively at down-regulating c-Myc and HIF-1a protein
levels
We examined the effect of 5 mM DCA and 5 μM ATO
treatment (12 hours) on the expression c-Myc and HIF-
1a, two major transcription factors that are known to
regulate the Warburg effect [33] and mitochondrial activ-
ity [34], and on the expression of the mitochondrial pro-
teins ATP synthase b subunit (ATPb) and Bcl-2.
Immunoblotting for c-Myc showed no change after treat-
ment with DCA while ATO induced the up-regulation of
c-Myc (Figure 7A and 7B), however ATO in combination
with DCA reduced c-Myc level compared to the
untreated control. HIF-1a levels on the other hand
showed a down regulation after both DCA and ATO
treatment. The combination of ATO and DCA showed
further down-regulation of HIF-1a compared to single
agent treated and control groups (Figure 7A and 7C).
Bcl-2 is a member of the BH3 protein family that binds
directly to Bad and Bax and prevents apoptosis [35].
Immunoblotting performed for ATPb found that DCA
treatment up-regulated ATPb while ATO showed an
opposite effect, lowering ATPb levels (Figure 7A
Figure 6 Effect of the MTP blockers CsA and BA on ATO treated cells. (A) CsA and BA can both partially block 20 μM ATO induced caspase
3/7 activation. (B to D) In contrast, CsA and BA both failed to block the NaCN or 5 μM ATO induced reduction in ROS (B), reduction in ATP
levels (C) and depolarization of the MMP (D). * P ≤ 0.05, ** P ≤ 0.001, *** P ≤ 0.0001 (treated vs untreated). # P ≤ 0.05, ## P ≤ 0.001 (compared
to ATO alone). NS - not significant compared to ATO or NaCN alone.
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Figure 7 Protein expression changes after ATO and DCA treatment. (A) Immunoblotting of T-47D cells treated with ATO and/or DCA. (B-E)
Densiometric analysis for c-Myc (B), HIF-1a (C), ATPb (D), Bcl-2 (E) and b-actin (control) was done on blotting of whole cell lysates prepared
from T-47D cells treated with 5 mM DCA and/or 5 μM ATO for 12 hours. * P ≤ 0.05, ** P ≤ 0.001, *** P ≤ 0.0001, NS - not significant (treated vs
untreated). # P ≤ 0.05, ## P ≤ 0.001, ### P ≤ 0.0001 (DCA/ATO vs ATO).
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and 7D), and ATO and DCA combined treatment
showed an intermediate response compared to ATO or
DCA treated groups. Immunoblotting for the pro-survi-
val protein Bcl-2 showed an up-regulation after DCA,
down-regulation for ATO treatment, and an intermediate
response from the combination of the two drugs (Figure
7A and 7E). These results are also very similar to ATP
levels and ROS production where DCA and ATO had
opposing effects (Figure 2C and 3B). The Bcl-2 and
ATPb results directly correlate with DCA and ATO’s
ability to influence ROS production and ATP levels.
Discussion
During the last decade, ATO has been used effectively
to treat both newly diagnosed and relapsed APL
patients, with patients showing complete remission after
low dose ATO treatment [4]. The anti-cancer ability of
ATO is not limited to APL [36] and many other tumors
in animal models have been shown to be sensitive to
ATO treatment [37,38]. However, the lack of informa-
tion on sites of action for ATO cytotoxicity in tumor
types other than APL has limited its uptake for the
treatment of other cancers until recent years [5].
In this study, we have demonstrated that complex IV of
the ETC is a target for ATO. From a panel of ETC inhibi-
tors, the decrease in ROS, decrease in ATP production
and MMP depolarisation caused by low dose ATO treat-
ment of T-47D cells was reproduced only by cyanide, a
well characterised complex IV inhibitor (Figure 5). Direct
measurement of cytochrome C oxidase activity in whole
cells treated with ATO confirmed the ability of ATO to
inhibit this enzyme activity directly. The cytochrome C
oxidase complex of the ETC is known to have closely
spaced cysteine residues [39], and these are likely to react
with ATO.
Most cancer cells have up regulated ROS levels com-
pared to normal cells [40] and the ETC is considered the
major source of intracellular ROS. The reduction in ROS
of up to 60% by NaCN or ATO, demonstrated that com-
plex IV is responsible for the majority of ROS production
in T-47D cells. The oxidative stress of elevated ROS pro-
duction has been described as a double edged sword. A
moderate increase in ROS has been shown to be asso-
ciated with increased proliferative potential [41], increased
antioxidant enzymes such as glutathione transferase [42],
superoxide dismutase and catalase [43] and increased pro-
survival proteins such as Bcl-2 [42] and survivin [44].
However, intolerable amounts of ROS eventually leads to
cell death [45]. The reduction in ROS after 12 hours treat-
ment of 5 μM ATO also directly correlated with a
decrease in Bcl-2 levels (Figure 7E) suggesting that T-47D
cells are in an apoptotic resistant state due to elevated
ROS levels. Continued inhibition of complex IV of the
ETC will lead to the depolarisation of the MMP and
inhibition of ATP production. The cell death that follows
from this mitochondrial dysregulation will give rise to the
elevated ROS seen after 4 hours or at higher ATO concen-
tration (Figure 3C and 3D) as reported by others [46] after
ATO treatment. Thus elevated ROS is a consequence, not
the cause, of ATO induced cell death.
The previously proposed mitochondrial target for ATO
is the MTP. Zheng et al demonstrated that ATO induces
the opening of the MTP in isolated rat liver mitochondria
[11], leading to the proposal that MTP is responsible for
the release of ROS and the depolarization of the MMP
seen during arsenic treatment, and subsequent apoptosis
[47]. Our study does not exclude MTP as a target for
ATO. Our data indicate that inhibition of the MTP via
CsA and BA can partially block caspase 3/7 activation
induced by high concentration ATO, however the MTP
blockers failed to inhibit the depolarization of MMP and
the reduction in ROS and ATP levels caused by low con-
centration ATO. Thus although ATO can open the MTP,
alternative targets are required to explain the action of
ATO at low concentrations. Inhibition of the thioredoxin
system has been shown to occur in MCF-7 cells after
treatment with 2-5 μM ATO and may mediate some cellu-
lar effects of ATO at low concentrations [13], however this
mechanism would lead to increased oxidative stress, and
cannot explain the decreased ROS observed in the current
study.
DCA, as a pyruvate dehydrogenase kinase inhibitor, can
reverse the glycolytic effect and has demonstrated signifi-
cant anti-cancer properties both in vitro and in vivo
[17-23]. Some studies show increased apoptosis with DCA
[17,18,20]. However our studies in breast cancer and stu-
dies by Stockwin et al indicate that DCA acts as a cyto-
static rather than cytotoxic agent across a range of cell
lines except at very high concentrations [22,48]. Michela-
kis recently reported trough serum levels of DCA to be 0.5
mM in glioblastoma patients taking 6.25 mg/kg orally
twice daily [23], thus the clinically relevant concentrations
are likely to be in the range of 0.5-5 mM. DCA has been
shown to induce a small but significant increase in caspase
3/7 activity even when apoptosis was not observed and it
was proposed that DCA may sensitize cancer cells towards
cytotoxic agents [22]. The current study confirmed this
hypothesis by showing that DCA sensitized T-47D cells
towards ATO treatment as seen from AV+/PI+ double
staining (Figure 1E and text). ATO was selected as the
agent for testing due to its anti-mitochondrial properties,
as we proposed that by reversing the glycolytic phenotype
with DCA, and directing more pyruvate into mitochon-
drial oxidative phosphorylation, while simultaneously tar-
geting the mitochondria with ATO, a cooperative effect
would be seen with this drug combination. The principle
of this dual targeting strategy is supported by the results
of two recent publications which found that cells with
Sun et al. Molecular Cancer 2011, 10:142
http://www.molecular-cancer.com/content/10/1/142
Page 12 of 15
mitochondrial defects (e.g. rho (0) or after treatment with
non-drug mitochondrial inhibitors such as rotenone) show
higher sensitivity to the growth inhibition effects of DCA
[48,49]. While the efficacy of this dual targeting strategy is
yet to be demonstrated in vivo, the ATO/DCA enhanced
combination effects were seen on both growth inhibition
and apoptosis at drug concentrations in clinically relevant
ranges. Some effects at the lower end of the concentration
range were not large (eg. 15% increase in apoptotic cells),
however the impact in vivo over weeks rather than hours
of treatment warrants further investigation.
It has been well documented that DCA can alter mito-
chondrial behavior i.e. depolarize the MMP [18,20]. How-
ever this phenomenon has not been well explained. We
observed that DCA can increase ATP while depolarizing
MMP in T-47D cells (Figure 2). Based on these data we
proposed that DCA is altering mitochondrial function
through complex V of the ETC, ATP synthase. ATP
synthase is the last step of the ETC and it uses the MMP
generated by the ETC to produce ATP. ATPb is down-
regulated in lung, brain, breast and gastric cancers [50],
which could explain the hyperpolarized mitochondrial
membrane that can be found in many cancer cells [51].
We have hypothesized that DCA can increase ATP
synthase activity either via allosteric regulation due to its
homology to pyruvate or via increase in ATP synthase
protein levels after the reversal of the Warburg effect and
decreased HIF-1a levels. Immunoblotting clearly demon-
strated that ATPb is up-regulated after DCA treatment
(Figure 7D) suggesting that DCA can increase ATP
synthase activity, which in turn contributes to increased
ATP production and exhaustion of the MMP.
HIF-1a and c-Myc are two major oncogenic transcrip-
tion factors known to regulate metabolism in cancer cells.
HIF-1a can up regulate the enzymes of the glycolytic
pathway and lactic acid dehydrogenase, sustaining the
Warburg effect in cancer cells [33]. This not only increases
ATP production, but also increases the supply of precur-
sors such as glucose-6-phophate and fructose-6-phosphate
for the production nucleic acids through the pentose
phosphate pathway [16]. c-Myc, on the other hand, not
only plays a central role in promoting G1 to S phase cell
cycle transition by regulating the cyclins and their kinases
and inhibitors, but also up regulates protein components
of the ETC such as COXI-IV and helps to increase mito-
chondrial activity [52]. Thus, the combination of c-Myc
and HIF-1a overexpression is important for inducing the
Warburg effect while increasing mitochondrial activity,
supporting the glutamine-TCA hub that is essential for
anabolism of amino acids and fatty acids needed for cell
division [16]. This metabolic signature contributes to car-
cinogenesis and the malignant phenotype of many tumors
[33,34]. Both ATO and DCA can decrease HIF-1a levels
significantly suggesting a reduction in the Warburg effect
(Figure 7C). While DCA alone had no effect on c-Myc
levels, surprisingly, ATO up regulated c-Myc levels signifi-
cantly (Figure 7B). This may be a positive feed back loop,
where the cells are trying to increase ETC activity after the
inhibition of complex IV. Strikingly, DCA reversed the
effect of ATO on c-Myc, and the combination of ATO/
DCA strongly repressed c-Myc expression, correlating
with the ability of these agents to work together at redu-
cing cell proliferation and inducing cell death (Figure 1).
The efficacy of ATO against PML has been attributed
to several special features of this malignancy - differentia-
tion through inactivation of PML-RARa, low antioxidant
capacity of PML cells to protect against the elevated ROS
levels, and accumulation of the drug due to impaired
osmoregulation [5]. Many trials are underway for the use
of ATO in a range of solid malignancies, although thus
far there are few results published. Results that are avail-
able suggest that ATO is not highly effective as a single
agent in patients with advanced cancer of the pancreas,
liver or melanoma [5]. Investigators are advocating evalu-
ating ATO in combination with other anticancer drugs
[53,54] with some phase I trials being completed [55]. As
our understanding of the mechanisms of ATO continues
to grow, especially its effects through cancer metabolism,
we may be better able to harness its anticancer potential
in vivo in novel drug combinations.
Conclusions
Two recent reports found DCA to be most effective
against cells with mitochondrial defects [48,49]. This
report is the first to demonstrate that targeting of two
aspects of metabolism - reversing of the Warburg effect
with DCA while inhibiting oxidative phosphorylation
with ATO - is clearly an effective anti-cancer strategy in
vitro against breast cancer cell lines. The identification of
cytochrome C oxidase as a mitochondrial target for ATO
provides novel mechanistic information for the applica-
tion of ATO to the treatment of tumor types other than
APL. The ability of DCA to increase ATP synthase b sub-
unit expression, reversing another widespread cancer
metabolic phenotype, also suggests DCA may be relevant
to a broad range of tumor types. The ability of DCA to
enhance the cytotoxic effects of chemotherapeutic agents
other than ATO in vitro and in vivo is also worthy of
further investigation. The lack of sensitivity of the non-
cancerous cell line MCF-10A to the clinically relevant
concentrations of ATO/DCA tested is also encouraging,
and suggests that this treatment strategy should be
further tested against solid tumors in vivo.
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